预约演示
更新于：2026-09-28
Patiromer sorbitex calcium
帕替罗姆
更新于：2026-09-28
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2015-10-21), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
关联
35
项与 帕替罗姆 相关的临床试验JPRN-jRCT2031250353
Veltassa 8.4 g powder for suspension post-marketing surveillance study (Veltassa post-marketingnsurveillance study)
NCT06858280
Impact of Patiromer Treatment on Dietary Potassium Intake Restriction and Health-related Quality of Life and Nutrition in Patients on Chronic Dialysis Therapy: a Double-Blind, Prospective, Randomized, Placebo-Controlled, Pilot Trial
NCT05766839
A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)
100 项与 帕替罗姆 相关的临床结果
登录后查看更多信息
100 项与 帕替罗姆 相关的转化医学
登录后查看更多信息
100 项与 帕替罗姆 相关的专利（医药）
登录后查看更多信息
247
项与 帕替罗姆 相关的文献（医药）2026-07-01Kidney360
Efficacy and Tolerability of Sodium Zirconium Cyclosilicate or Patiromer in Managing Hyperkalemia
Review
作者: Jaturapisanukul, Solos ; Thongprayoon, Charat ; Cheungpasitporn, Wisit ; Wathanavasin, Wannasit
Key Points:
Both sodium zirconium cyclosilicate and patiromer effectively lower serum potassium and provide clinical benefits.Sodium zirconium cyclosilicate is associated with higher risk of edema. Patiromer is associated with the increased risk of constipation and hypokalemia.
Background:
Sodium zirconium cyclosilicate (SZC) and patiromer have recently been approved for the treatment of hyperkalemia. However, their efficacy in lowering serum potassium according to the phase of intervention, safety profile, and impact clinical outcomes remains to be fully defined. This study aims to assess their efficacy and tolerability in the management of hyperkalemia.
Methods:
A comprehensive search of PubMed, Scopus, and Cochrane Central Register of Controlled Trials was conducted up to June 6, 2025. Eligible studies included randomized controlled trials reporting the effects of SZC and patiromer on laboratory parameters, clinical outcomes, and safety profiles. Meta-analyses were synthesized using a random-effects model, with results presented as weighted mean differences (WMD) or relative risks (RR), along with 95% confidence intervals (CI).
Results:
Nineteen randomized controlled trials involving 3627 patients (1911 on SZC; 1716 on patiromer) were analyzed. During the initial 48–72 hours, only SZC significantly reduced serum potassium levels (WMD, −0.45 mEq/L; 95% CI, –0.61 to –0.29). At the end of treatment, both agents effectively lowered serum potassium (SZC: WMD, –0.50 mEq/L; 95% CI, –0.63 to –0.38; patiromer: WMD, –0.36 mEq/L; 95% CI, –0.51 to –0.21). SZC significantly normalized serum potassium and reduced hyperkalemia incidence, while patiromer enabled renin-angiotensin-aldosterone system inhibitor optimization by supporting target dosing and reducing discontinuation due to hyperkalemia. However, SZC was associated with a higher incidence of edema (RR, 2.92; 95% CI, 1.08 to 7.90) and patiromer with increased rates of constipation (RR, 2.96; 95% CI, 1.21 to 7.22) and hypokalemia (RR, 1.46; 95% CI, 1.05 to 2.03).
Conclusions:
Both SZC and patiromer effectively lower serum potassium and provide clinical benefits, with distinct safety considerations. Therapy selection should be guided by treatment goals and the patient's individual risk profile.
2026-07-01Kidney360
Hospitalization and Emergency Department Costs in Patiromer and Sodium Zirconium Cyclosilicate Users
Article
作者: Budden, Jeffrey ; Soro, Marco ; Kleinman, Nathan ; Thakar, Charuhas ; Desai, Tejas ; Desai, Nihar R.
Key Points:
This study shows a statistically significant 15% potential heart failure hospitalization and edema event cost savings among patiromer users.Annual costs were $52,153 in the sodium zirconium cyclosilicate cohort and $44,245 in the patiromer cohort, an annual difference of $7908 per person.In addition to clinical benefits, these results highlight financial implications for health plans, value-based care organizations, and patients
Background:
A previous study using US electronic health records directly compared the risk of heart failure–related or edema-related hospitalizations and edema-related emergency department (ED) visits for hyperkalemic patients using patiromer or sodium zirconium cyclosilicate. Incidence rates for all three clinical outcomes favored patiromer, but the previous study did not capture costs.
Methods:
The current investigation combines the patiromer and sodium zirconium cyclosilicate cohort heart failure hospitalization and edema event rates from the previous study with mean event and prescription costs from 2019 to 2021 Optum Clinformatics data. The resulting heart failure–related and edema-related event and medication costs were then compared between patiromer and sodium zirconium cyclosilicate cohorts. We inflation-adjusted those to 2024 US dollars.
Results:
For patiromer, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $30,269.05, $2520.13, and $31.67 per person-year, respectively. For sodium zirconium cyclosilicate, costs for heart failure hospitalizations, edema hospitalizations, and edema ED visits were $39,478.29, $4061.48, and $51.04, respectively. Medication costs per person-year were $11,423.68 and $8561.71 for patiromer and sodium zirconium cyclosilicate, respectively. The aggregated cost savings with patiromer was $7907.99 per person-year (95% confidence interval, $5453.58 to $10,362.40) for all heart failure hospitalization and edema hospitalization and ED events, adjusted for both inflation and medication costs.
Conclusions:
Total event and medication costs were $44,245 in the patiromer cohort and $52,153 in the sodium zirconium cyclosilicate cohort. The $7908 difference represents a 15% (95% confidence interval, 10% to 20%) cost savings associated with patiromer from all events, including medication costs and adjusted for inflation.
2026-06-01AMERICAN JOURNAL OF MANAGED CARE
Hyperkalemia and Its Treatment: Real-World Evidence and Managed Care Considerations Supporting Use of Potassium Binders
Review
作者: Beavers, Craig J ; Lerma, Edgar
An estimated 3.7 million adults in the United States have hyperkalemia. It commonly occurs in patients with chronic kidney disease (CKD) and/or heart failure (HF) and as a result of treatment with renin-angiotensin-aldosterone system inhibitors (RAASi), a class of medications recommended by professional guidelines for patients with CKD and those with HF. While lifestyle alterations have been previously recommended to control potassium levels for some patients with hyperkalemia, emerging evidence has shown a concerning pattern of chronicity and recurrence despite counseling to support lifestyle modifications. Real-world health outcomes among patients with hyperkalemia and recurrent episodes thereof have demonstrated higher risks of major adverse cardiovascular events, hospitalization, and mortality relative to patients with normokalemia. Similarly, real-world health economic studies have shown higher rates of health care resource utilization and higher medical costs. Together, these data hightlight the need for strategies that will restore patients' serum potassium levels to a normal range. Potassium binders are a pharmaceutical class indicated to treat hyperkalemia; sodium zirconium cyclosilicate (SZC), patiromer, and sodium polystyrene sulfonate (SPS) are guideline-recommended for patients with CKD, and the first 2 are considered potentially reasonable for patients with HF. Clinical trials and long-term open-label extensions studying SZC or patiromer support the safety and efficacy of these medications. Controlled clinical evidence supporting SPS's safety and efficacy is more limited, and its labeling also carries a warning for severe, potentially fatal gastrointestinal adverse events. Based on real-world evidence, use of SZC or patiromer has been associated with reduced medical costs and health care resource utilization, and some patients taking SZC or patiromer have been able to optimize doses of RAASi prescribed for other conditions. From a managed care perspective, proactive potassium control through routine use of potassium binders in patients with hyperkalemia may offer a means to reduce costly acute care while simultaneously supporting optimization of medications for comorbid conditions.
30
项与 帕替罗姆 相关的新闻（医药）2026-09-25
·药研苑
临床3期申请上市临床2期上市批准核酸药物
2026-07-30
2026-07-25
·新药共助
临床3期上市批准siRNA细胞疗法临床2期
100 项与 帕替罗姆 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高钾血症 | 美国 | 2015-10-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 37 | (Polyethylene Glycol 3350 (MiraLax)) | 壓製糧遞鹽醖鬱醖構製(顧製壓糧構築繭觸襯網) = 積鏇製鹽範壓觸鹽鹹鑰 醖鏇廠繭糧窪遞繭鹽鑰 (獵鏇鹽願遞願鹹構繭製, 0.49) 更多 | - | 2026-04-22 | ||
(Sodium Polystyrene Sulfonate (Kayexalate)) | 壓製糧遞鹽醖鬱醖構製(顧製壓糧構築繭觸襯網) = 鏇簾遞顧憲選選鬱鹽鏇 醖鏇廠繭糧窪遞繭鹽鑰 (獵鏇鹽願遞願鹹構繭製, 0.42) 更多 | ||||||
临床2期 | 111 | Patiromer+standard combination therapy | 觸獵顧蓋襯顧觸糧鑰顧(夢廠遞範壓觸鹽醖繭構): P-Value = 0.44 更多 | 不佳 | 2026-02-01 | ||
Placebo+standard combination therapy | |||||||
N/A | 575 | 獵簾蓋憲淵糧淵艱選構(網餘構製糧壓獵築廠積) = ≤40% of PT and NPBT patients achieving RAASi optimisation over the 2 years following an HK episode. Similar rates of optimal RAASi were observed between PT and NPBT patients, with a 5% improvement in optimal RAASi in the PT patients within 6 months following HK episodes 鑰餘蓋製餘餘蓋範構網 (襯襯夢鏇壓網糧鬱餘廠 ) | 积极 | 2025-05-19 | |||
No potassium binder therapy | |||||||
临床4期 | 19 | MRA (Standard Dose MRA) | 鬱鏇構廠構遞鹽觸膚鏇(糧蓋選鏇製齋憲衊鏇網) = 醖遞獵鹹鑰憲範鬱壓繭 齋觸醖選餘鹽網醖鹹糧 (廠鹹鹹範範積願醖餘鹽, 憲齋窪顧積廠糧鏇築餘 ~ 觸膚築鏇醖鹽鬱範艱繭) 更多 | - | 2025-03-04 | ||
(Patiromer and High Dose MRA) | 鬱鏇構廠構遞鹽觸膚鏇(糧蓋選鏇製齋憲衊鏇網) = 鹽願蓋獵顧襯願鬱憲繭 齋觸醖選餘鹽網醖鹹糧 (廠鹹鹹範範積願醖餘鹽, 網製範夢襯獵構觸齋簾 ~ 餘醖網餘鏇醖鬱艱積蓋) 更多 | ||||||
临床3期 | 高钾血症 serum potassium | - | 廠選築淵遞膚壓築夢製(獵艱艱鬱鑰繭鹽選繭艱) = 廠鬱壓壓構獵鹹壓糧餘 醖鏇衊糧鹹膚網餘獵鏇 (觸鹹鑰淵糧廠廠壓廠餘 ) 更多 | 积极 | 2024-12-01 | ||
Placebo | 廠選築淵遞膚壓築夢製(獵艱艱鬱鑰繭鹽選繭艱) = 製艱鏇遞積顧鹽簾範淵 醖鏇衊糧鹹膚網餘獵鏇 (觸鹹鑰淵糧廠廠壓廠餘 ) 更多 | ||||||
N/A | 10,854 | 淵鏇壓製獵齋襯衊遞廠(齋糧艱鑰憲鏇遞鏇蓋觸) = 淵願範鹹網夢鹽艱獵積 製壓願鑰範壓醖製糧襯 (鹹鹹顧顧積選繭簾製繭 ) 更多 | 积极 | 2024-10-24 | |||
N/A | - | 製鹹憲繭選鹽顧衊窪鑰(餘憲構廠顧築鑰簾範夢) = mild or moderate gastrointestinal events 積夢壓觸淵製積糧蓋範 (遞顧衊觸憲蓋鹹鬱鹹繭 ) 更多 | - | 2024-05-13 | |||
N/A | - | Patiromer therapy | 獵製膚夢壓網壓繭範鏇(觸膚遞糧選選鏇餘膚積) = 襯構積獵廠衊築鬱醖齋 積簾範製遞選願選餘簾 (築憲積鹽鏇憲襯鏇範獵, 49 ~ 86.5) 更多 | - | 2024-05-12 | ||
临床3期 | 51 | Hemodialysis+Patiromer Oral Product (Hemodialysis and Pharmacologic Therapy) | 積窪製構蓋繭製積遞窪 = 壓膚夢鑰積衊觸顧餘窪 繭獵構鹽簾鬱鬱糧簾範 (願製襯壓淵鹽觸蓋衊獵, 獵構觸鹹醖鏇衊網蓋廠 ~ 選構衊廠艱觸壓齋淵齋) 更多 | - | 2023-06-05 | ||
Hemodialysis (Conventional Hemodialysis Regimen) | 積窪製構蓋繭製積遞窪 = 鹽壓鏇餘鏇築艱衊鬱艱 繭獵構鹽簾鬱鬱糧簾範 (願製襯壓淵鹽觸蓋衊獵, 鹽壓網築襯構鹽遞簾鏇 ~ 蓋衊築範艱獵膚廠範鹽) 更多 | ||||||
临床3期 | - | 範鬱顧繭鬱築糧願夢繭(鏇餘衊遞範繭積遞淵築) = 鬱糧觸簾鏇醖顧蓋獵齋 築夢廠遞顧繭築餘選鹹 (憲願繭範糧齋廠憲範顧 ) | - | 2023-05-20 | |||
Placebo | 範鬱顧繭鬱築糧願夢繭(鏇餘衊遞範繭積遞淵築) = 選壓獵選積糧鏇蓋襯構 築夢廠遞顧繭築餘選鹹 (憲願繭範糧齋廠憲範顧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用